Αρχειοθήκη ιστολογίου

Αναζήτηση αυτού του ιστολογίου

Τρίτη 29 Νοεμβρίου 2022

The third inactivated vaccine booster dramatically enhanced SARS‐CoV‐2 antibody responses and did not influence the profile of prothrombotic antibody

alexandrossfakianakis shared this article with you from Inoreader

Abstract

Objective

The purpose of this study is to investigate the production of both SARS-CoV-2-specific antibodies and autoantibodies in serum following the third booster vaccination of the inactivated COVID-19 vaccine, and to study the effect of B cell subsets with CD27 and CD38 phenotypes in peripheral blood on antibody production.

Methods

Routine blood indexes, SARS-CoV-2 antibodies, platelet factor 4 and seven antiphospholipid antibodies were detected both before and 2 months after vaccination in the medical staff of the Zhongnan Hospital of Wuhan University. Peripheral blood B cell subtypes were detected prior to vaccination.

Results

Following immunization, the positive rate of anti-N-S1 IgG had increased from 24.8% to 91.3% and the average antibody concentration had increased by 11 times. The positive rate of NAb had increased from 24.8% to 91.3%, the average antibody concentration had increased by 12 times, and the primary increased anti-S1 IgG subtype was that of IgG1. Peripheral blood CD27+CD38+ B cells were positively correlated with antibody levels after vaccination and were a predictor of the antibody response. In addition, although some indicators showed slight absolute changes, the blood parameters and antiphospholipid antibodies of most volunteers were normal both before and after COVID-19 inactivated vaccine inoculation, and there was no statistical difference in abnormal rates either before or after inoculation.

Conclusion

Antibodies in vivo were increased after vaccination with the inactivated vaccine, and IgG1 was the main subtype involved in response to the vaccine. Vaccination with the inactivated COVID-19 vaccine did not appear to affect thrombus-related autoantibodies.

This article is protected by copyright. All rights reserved.

View on Web

Concomitant administration of warfarin and toremifene: A case report

alexandrossfakianakis shared this article with you from Inoreader
Concomitant administration of warfarin and toremifene: A case report

We reported a 50-year-old woman who was treated with warfarin after prosthetic valve replacement and had a fluctuating international normalized ratio (INR) following the concomitant administration of toremifene. The results suggested when concomitant administration of warfarin and to remifene, the interaction between them is not serious, but the dose of warfarin needs to be reduced.


Abstract

What Is Known and Objective

Antiestrogen agents have been reported to enhance the anticoagulant activity of warfarin. The use of tamoxifen with warfarin has been contraindicated. However, warfarin in combination with toremifene has not been reported. We report a case in which warfarin was combined with toremifene and applied warfarin dose prediction models to predict the dose of warfarin.

Case Summary

We report the case of a 50-year-old woman with a history of breast cancer, who underwent long-term toremifene therapy after mastectomy. The patient was treated with warfarin after prosthetic valve replacement and had a fluctuating international normalized ratio (INR) following the concomitant administration of toremifene. We applied the warfarin dose prediction model to adjust the warfarin dose during treatment. Finally, her INR stabilized with a lower dose of warfarin, and there was no serious bleeding during the 1-year follow-up.

What Is New and Conclusion

Warfarin does not have a serious interaction with toremifene in this case, but it needed about 37.5% dose reduction which was comparable to the interaction of some common antibiotics with warfarin.

View on Web

Differential Associations of Rheumatoid Arthritis and Periodontitis or Tooth Loss: A Cross‐Sectional Study

alexandrossfakianakis shared this article with you from Inoreader

Abstract

Aims

To study the association between periodontitis, tooth loss, and rheumatoid arthritis by using a large national dataset.

Materials and Methods

An observational cross-sectional study was performed using the National Health and Nutrition Examination Survey (NHANES) cycles (2009-2014). Rheumatoid arthritis status was detected by a questionnaire. Periodontal status was assigned based on clinical attachment level and periodontal pocket depth. Dentition status was assessed by the number of permanent teeth observed. We examined the association between rheumatoid arthritis as exposure and moderate/severe periodontitis and non-functional dentition as outcomes. We progressively adjusted our models for different sets of potential confounders.

Results

Moderate/severe periodontitis was more prevalent in participants reporting rheumatoid arthritis (53% vs. 41.5%, p= 0.0003). Non-functional dentition was more prevalent in participants with rheumatoid arthritis (41% vs. 15.5%, p= 0.0001). The fully adjusted model showed participants with rheumatoid arthritis had higher odds of having a non-functional dentition (Odds Ratio 1.8, 95% CI 1.3-2.3, p= 0.0001), but no association with moderate/severe periodontitis (Prevalence Ratio 1.01, 95% CI 0.9-1.1, p= 0.9).

Conclusion

Rheumatoid arthritis was associated with a higher likelihood of having non-functional dentition but did not show an association with periodontitis after adjustments of the risk factors to control their confounding effect.

View on Web

Mechanical properties of platelet-rich fibrin from patients on warfarin

alexandrossfakianakis shared this article with you from Inoreader
Platelet-rich fibrin (PRF) has been used increasingly in oral and maxillofacial surgery in recent years. The aim of this experimental study was to perform a mechanical evaluation of PRF from patients on warfarin. PRF samples were obtained from 21 patients on warfarin (mean INR 2.30  ± 0.89) and 21 non-anticoagulated patients (control; mean INR 1.08 ± 0.07). For the patients on warfarin, two experimental groups were formed based on the PRF centrifugation time: group A, 10 min (21 samples); group B, 18 min (20 samples). (Source: International Journal of Oral and Maxillofacial Surgery)
View on Web